Axsome Therapeutics (AXSM) EBT Margin (2022 - 2026)

Axsome Therapeutics has disclosed EBT Margin across 5 years of filings, most recently posting 33.76% for Q1 2026.

• EBT Margin for Q1 2026 came in at 33.76%, up 1516.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 26.66% (up 6196.0% YoY), and the FY2025 annual result was 28.77%, up 4567.0% from the prior year.
• EBT Margin came in at 33.76% for Q1 2026 at Axsome Therapeutics, down from 14.35% in the prior quarter.
• In the past five years, EBT Margin ranged from a high of 9.13% in Q1 2023 to a low of 14965.4% in Q4 2024.
• The 5-year median for EBT Margin is 91.09% (2024), against an average of 1047.2%.
• Across the five-year window, EBT Margin sank 1482703 bps in 2024 and surged 1495105 bps in 2025, its largest moves.
• Axsome Therapeutics' EBT Margin stood at 251.29% in 2022, then soared by 45 bps to 138.37% in 2023, then tumbled by 10716 bps to 14965.4% in 2024, then surged by 100 bps to 14.35% in 2025, then slumped by 135 bps to 33.76% in 2026.
• The last three EBT Margin figures came in at 33.76% (Q1 2026), 14.35% (Q4 2025), and 27.62% (Q3 2025), per Business Quant data.